Compare Amgen, Inc. (AMGN) vs Coinbase Global, Inc. (COIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Coinbase Global, Inc. — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while Coinbase Global, Inc. trades at $156.8 (market cap $41.91B). The key difference: Amgen, Inc. is far larger — about 4.7× Coinbase Global, Inc.'s market cap, and Amgen, Inc. pays a 2.77% dividend while Coinbase Global, Inc. pays none. Which is the better fit depends on your goals.
| AMGN | COIN | |
|---|---|---|
Market Cap | $196.12B | $41.91B |
Sector | Health | Technology |
52-Week High | $388.16 | $419.78 |
52-Week Low | $271.18 | $141.09 |
Enterprise Value | $241.41B | $39.19B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
COIN trades at $159.07, up 0.4% on the day, with a bearish technical signal from moving averages despite neutral oscillators. The company reported mixed Q1 2026 earnings, missing estimates, but maintains strong revenue growth and a 73.32% gross margin. Analyst consensus remains bullish with a $230.15 price target, supported by recent regulatory developments like Circle's OCC trust bank approval (Reuters, 2026-07-10).
The outlook is cautiously optimistic given analyst support and improving cash flows, but risks include earnings volatility and regulatory uncertainty. Investment opportunity hinges on execution amid competitive pressures, with the stock offering potential upside if operational trends stabilize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Coinbase Global, Inc.
Coinbase Global, Inc. is a regulated cryptocurrency company that provides customers around the world with a platform for buying, selling, transferring, and storing digital assets. The Company offers a variety of products and services that enable individuals, businesses, and developers to participate in the cryptoeconomy.
Read more on COIN →
